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Background: Neuromyelitis optica (NMO) is a severely disabling inflammatory disorder of the central nervous
system and is often misdiagnosed as multiple sclerosis (MS). There is increasing evidence that treatment options
shown to be beneficial in MS, including interferon-β (IFN-β), are detrimental in NMO.
Case presentation: We here report the first Caucasian patient with aquaporin 4 (AQP4) antibody (NMO-IgG)-
seropositive NMO presenting with a tumefactive brain lesion on treatment with IFN-β. Disease started with
relapsing optic neuritis and an episode of longitudinally extensive transverse myelitis (LETM) in the absence of any
brain MRI lesions or cerebrospinal fluid-restricted oligoclonal bands. After initial misdiagnosis of multiple sclerosis
(MS) the patient received subcutaneous IFN-β1b and, subsequently, subcutaneous IFN-β1a therapy for several years.
Under this treatment, the patient showed persisting relapse activity and finally presented with a severe episode of
subacute aphasia and right-sided hemiparesis due to a large T2 hyperintensive tumefactive lesion of the left brain
hemisphere and a smaller T2 lesion on the right side. Despite rituximab therapy two further LETM episodes occurred,
resulting in severe neurological deficits. Therapeutic blockade of the interleukin (IL)-6 signalling pathway by
tocilizumab was initiated, followed by clinical and radiological stabilization.
Conclusion: Our case (i) illustrates the relevance of correctly distinguishing NMO and MS since these disorders
differ markedly in their responsiveness to immunomodulatory and -suppressive therapies; (ii) confirms and extends
a previous report describing the development of tumefactive brain lesions under IFN-β therapy in two Asian NMO
patients; and (iii) suggests tocilizumab as a promising therapeutic alternative in highly active NMO disease courses.
Keywords: Neuromyelitis optica, Aquaporin-4 antibodies (NMO-IgG), Interferon-beta, Tocilizumab, Interleukin-6,
Rituximab, Azathioprine, Methylprednisolone, Tumefactive brain lesions, Multiple sclerosisBackground
Interferon-β (IFN-β) is one of the established first-line
therapies for patients with relapsing-remitting multiple
sclerosis (MS). While the efficacy of IFN-β in MS is
widely accepted, the possible benefit in non-classical
MS variants has been disputed. This is the case for neu-
romyelitis optica (NMO/Devic’s syndrome), considered
an MS subtype until the discovery of the anti-aquaporin 4
(AQP4) antibodies (AQP4-Ab) [1,2]. In both Asian and* Correspondence: orhan.aktas@hhu.de
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unless otherwise stated.European NMO patients, IFN-β failed to show therapeutic
efficacy [3-5]. Of note, Shimizu and colleagues recently re-
ported two Asian patients with NMO spectrum disease
(NMOSD) who developed extensive brain lesions fol-
lowing IFN-β therapy [6]. Here we report the case of an
AQP4 Ab-seropositive NMO patient of Caucasian des-
cent presenting with a tumefactive lesion on IFN-β
treatment. Of note, our patient did not respond to B cell
depletion by the monoclonal anti-CD20 antibody rituxi-
mab but improved upon blockade of the interleukin (IL)-6
pathway using tocilizumab.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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A 47-year old Caucasian female patient had been diag-
nosed with MS in 1995 in an external hospital after
four episodes of optic neuritis (ON) since 1989 and an
episode of longitudinally extensive transverse myelitis
(LETM) in 1995 (Figure 1). Cerebrospinal fluid (CSF)-
restricted oligoclonal bands (OCBs) were repeatedly
negative and brain MRI scans did not show any1989 1993 1997
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Figure 1 Disease course, MRI scans and therapy in a patient with AQP
MRI findings (T2, FLAIR), and therapy data (methyl prednisolone (MP) 1000
month; rituximab 1000 mg i.v. (single infusion), IFN (interferon)-β1a 44 μg s.c.
methylpredisolone 250 mg i.v. once per month; azathioprine (AZA)). No relaps
AQP: aquaporin, AZA: azathioprine, FLAIR: fluid attenuated inversion recovery,
imaging, MS: multiple sclerosis, NMO: neuromyelitis optica.abnormalities (e.g. MRI performed in 2001, Figure 1).
After an initial two months azathioprine treatment in
1995, which had to be discontinued because of side ef-
fects, repeated monthly intravenous (iv) steroid pulse
treatments with 250 mg methylprednisolone (MP) were
initiated and continued until April 2013. In 2001, after
three further episodes of ON, subcutaneous IFN-β1b
medication was added to the ongoing steroid pulse2001 2005 2009 2013 2014
normal
is AQP4+
4-Ab-positive NMO. The figure depicts clinical relapses (diamonds),
mg i.v. 3–5 daily infusions; tocilizumab 8 mg/kg bodyweight once a
three times a week (Rebif®); IFN-β1b s.c. daily (Betaferon®, Betaseron®);
es have occurred during therapy with tocilizumab (follow-up: 12 months).
IFN: interferon, MP: methyl prednisolone, MRI: magnetic resonance
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to subcutaneous IFN-β1a (3 × 44 μg/week). During
IFN-β therapy the patient still suffered from further re-
lapses, most of them occurring between the years 2001
and 2005 (July 2002, February 2005, and April 2005).
She recovered only partially from the relapses and accu-
mulated fixed neurological deficits such as amaurosis of
the right eye and impaired walking with an expanded
disability status scale (EDSS) score of 4.0 in January
2012. Of note, there was no chronic progression be-
tween the relapses. In 2011 persisting disease activity
prompted testing for serum AQP4 antibodies (by a cell-
based assay; CBA [7]) which were found positive and
confirmed the diagnosis of seropositive NMO. Follow-
ing the patient’s wishes and in light of the reduced
relapse rate since 2005 therapy with subcutaneous IFN-
β1a was continued, together with the regular monthly
steroid therapy (250 mg MP each) established since
1995. In January 2012, she suffered from a subacute
aphasia and right sided hemiparesis and presented to
our department. MRI imaging showed a large T2 hyper-
intensive, tumefactive lesion in the prefrontal white
matter of the superior and middle frontal gyrus of the
left hemisphere and smaller T2 lesions on the right
side without clear evidence of a disturbed blood brain
barrier (Figure 1). MR spectroscopy showed an unchanged
choline peak and thus did not give a hint to a malignant
process. Analysis of CSF was unremarkable with still
no quantitative evidence for intrathecal immunoglobu-
lin (Ig) synthesis or OCBs and a normal CSF white cell
count. AQP4-Ab serum titre was 1:1000 (CBA). Fur-
thermore, a time-of-flight MR-angiography showed no
signs of vasculitis, and laboratory work-up revealed no
clinical or serological evidence for connective tissue
diseases. The patient received a high-dose methylpred-
nisolone iv pulse and clinically improved. The follow-up
MRI one month later showed a mild regression of the
large T2 hyperintense lesion. We stopped IFN-β therapy
and continued the already existing monthly steroid pulses
(250 mg MP each) as the patient declined any additional
medication at that time. However, two attacks of myelitis
occurred in March 2013 and April 2013. Follow-up
AQP4-Ab testing in April 2013 confirmed seropositivity
(1:1000; CBA). The patient was treated with high-dose
steroid iv pulse therapy and rescue plasmapheresis. There-
after our patient agreed to an adaptation of therapy and
the monthly steroid infusions were discontinued without
tapering.
We initiated treatment with rituximab (single intra-
venous infusion of 1000 mg) in May 2013 and trans-
ferred our patient to a rehabilitation centre. However,
further severe LETM attacks occurred shortly thereafter
in June and August 2013. The patient was re-admitted
to our department in September 2013 and showedpersistently increased AQP4-Ab titres (1:3200, CBA).
Absolute B cell counts were normal (68/μl) while rela-
tive proportion was decreased (3% of all lymphocytes;
reference value 5-24%). This relapse was associated with
a urinary tract infection (without systemic signs of inflam-
mation, i.e. without leucocytosis, fever or elevated C-react-
ive protein (CRP) levels) which we successfully treated
according to local guidelines. In light of the patient’s se-
vere clinical deficits (EDSS of 9.0) we applied another iv
steroid pulse and decided to switch to tocilizumab, a hu-
manized monoclonal anti-IL-6-receptor antibody. Monthly
infusions of tocilizumab with 8 mg/kg bodyweight were
followed by clinical stabilization as no further relapses oc-
curred for the following 12 months (see clinical and MRI
follow-up after withdrawal of IFN-β in Figure 1). We also
observed a slight clinical improvement, as reflected by an
EDSS of 8.0. Of note, serum AQP4 antibodies were still de-
tectable at high titre at last follow-up in October 2014
(1:3200, CBA).
Conclusions
To our knowledge, we here present the first Caucasian
NMO patient who developed a tumefactive brain lesion
on long-term IFN-β treatment. Our case confirms and
extends similar findings in two Asian NMOSD patients
recently reported by Shimizu and colleagues [6]. Obvi-
ously the development of a tumefactive brain lesion
during IFN-β therapy of NMO is not linked to a specific
ethnicity. Moreover, in line with results obtained previ-
ously in other cohorts, our patient experienced numer-
ous relapses under IFN-β therapy. Why NMO patients
fail to respond to IFN-β remains so far unclear. Possible
explanations consider the complex immunomodulatory
effects of IFN-β, including the upregulation of proin-
flammatory cytokines observed in MS [8]. Since in
NMOSD higher CNS levels of IL-17 are observed than
in MS [9], it may be speculated that IL-17 biology may
play a role in NMO unresponsiveness to IFN-β. More-
over, a recent study in NMO patients could link serum
levels of IFN-α, a type I interferon closely related to
IFN-β, with clinical disease activity and severity [10]. Inde-
pendent experimental work demonstrated that NMO-
IgG-mediated astrocyte damage is reduced in the CNS of
type I interferon receptor deficient mice, suggesting that
type I interferon signalling contributes to the pathogenesis
of neuromyelitis optica [11].
Of note, administration of a single intravenous infu-
sion of 1000 mg rituximab was followed by further re-
lapses just one and three months later. While CD19
counts were not determined directly after rituximab
application, an investigation four months after rituxi-
mab dosing showed normal absolute B cell counts and
persistently increased AQP4-Ab levels. We may specu-
late that our patient belongs to individuals characterized
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ing rituximab therapy [12].
Our case adds preliminary evidence in favour of a
possible beneficial effect of tocilizumab in NMO, even
following treatment with rituximab [13-15]. However,
considering that NMO is often characterized by very
long periods free of any relapses, the suggested success
of tocilizumab in our patient needs to be followed up.
Moreover, more studies, in particular independent con-
trolled trials, are required to confirm the efficacy of
tocilizumab in NMO suggested by this case report and
previous ones [13-16]. The demonstration of signifi-
cantly increased levels of IL-6 in comparison to MS in
the CSF and serum of patients with NMO [17,18], par-
ticularly in AQP4 Ab-seropositive patients with severe
disease activity [18], provides a rationale for the use of
this drug in NMO. In an ex vivo experimental model of
NMO spinal cord slice cultures exposed to NMO-IgG and
complement showed a marked loss of AQP4 and myelin
which was enhanced by adding IL-6 [19]. Moreover,
Chihara and colleagues described a specific IL-6-dependent
B lymphocyte subpopulation in the peripheral blood
and CSF of NMO patients: these CD19+ CD27+ CD38+
CD180+ B cells were found to produce AQP4 antibodies
and showed enhanced survival as well as AQP4 anti-
body secretion in the presence of IL-6, whereas blockage
of the IL-6 receptor signalling by an anti-IL-6R antibody
shortened their survival in vitro [20].
Our report illustrates the importance of correctly
diagnosing NMO and MS to avoid mistreatment with
potentially severe or even fatal consequences. Two re-
cent studies have revealed that up to 30% of patients
with NMO were falsely diagnosed with MS [21,22] and,
in consequence, often treated with drugs not effective
in NMO. While AQP4-IgG serum testing is certainly the
most important differential diagnostic measure, other in-
vestigations such as lumbar puncture or brain and spinal
cord MRI are important as well. In the present case,
the diagnosis of MS was made in the absence of CSF-
restricted OCBs. OCB negativity is extremely rare in
MS (~2-5%) and should prompt physicians to question
that diagnosis; by contrast, around 70% of patients with
AQP4-IgG-positive NMOSD lack OCBs [22-24]. Nor-
mal CSF/serum concentration quotient values of IgG
(QIgG) in NMOSD are especially common during pe-
riods of clinical remission [23]. Similarly, a persistently
normal brain MRI as observed in our patient should
warn against the diagnosis of MS [25]. Brain lesions
are absent in most patients with NMO at disease onset,
but may occur later in the disease and may even meet
MRI criteria for MS [23,26]. Of note, for Asian NMO
patients, independent case reports described the oc-
currence of hemispheric brain lesions even without
association to IFN-β therapy [27-29], while we are notaware of such observations for NMO patients of other
ethnic background. Finally, predominantly central, lon-
gitudinally extensive spinal cord lesions extending over
more than three vertebral segments are extremely rare
in MS while their presence is highly suggestive of
NMOSD [30].
Our case supports the conclusion that the develop-
ment of tumefactive brain lesions under IFN-β therapy
for suspected MS should prompt considering NMOSD
as the underlying disease, obviously not only in Asian but
also in Caucasian patients. Moreover, our report under-
lines – in accordance with previous reports and recom-
mendations [31] – the need to treat MS and NMO, two
conditions with substantial differences in pathogenesis
[32,33] differentially and, in particular, to avoid treatment
with IFN-β in patients with NMO. Our report adds to pre-
vious evidence indicating a potential treatment effect of
tocilizumab, an IL-6 signalling pathway blocker in
NMO therapy.Consent
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